Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)

The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second- or third-line treatment for elderly Japanese patients with non-small-cell lung cancer (NSCLC). The patients eligible for this phase II tria...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Clin Oncol
Päätekijät: Miyawaki, Masayoshi, Naoki, Katsuhiko, Yoda, Satoshi, Nakayama, Sohei, Satomi, Ryosuke, Sato, Takashi, Ikemura, Shinnosuke, Ohgino, Keiko, Ishioka, Kota, Arai, Daisuke, Namkoong, Ho, Otsuka, Kengo, Miyazaki, Masaki, Tani, Tetsuo, Kuroda, Aoi, Nishino, Makoto, Yasuda, Hiroyuki, Kawada, Ichiro, Koh, Hidefumi, Nakamura, Morio, Terashima, Takeshi, Sakamaki, Fumio, Sayama, Koichi, Betsuyaku, Tomoko, Soejima, Kenzo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: D.A. Spandidos 2017
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5403701/
https://ncbi.nlm.nih.gov/pubmed/28451422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1154
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia